FDA Inspection 1122517 — Egbert F. Smit, M.D., PhD
The FDA completed an inspection of Egbert F. Smit, M.D., PhD on February 28, 2020 in Amsterdam. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI) (NAI)
- End Date
- February 28, 2020
- Fiscal Year
- 2020
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Amsterdam (Netherlands)
Additional Details
Clinical Investigator (CI)